Medina MM

Language: Spanish
References: 23
Page: 47-52
PDF size: 146.20 Kb.

Text Extraction

No Abstract

REFERENCES

1. Isbister JP. Therapeutic Apheresis. Indian J Pediatr 2001;68(1):61-67.

2. 2. Gorlin JB. Therapeutic plasma exchange and cytapheresis in pediatric patients. Transfus Sci 1999; 21:21-39.

3. 3. Castellá CM. Recambio plasmático terapéutico. Sangre 1999;44(1):76-79.

4. 4. Council on Scientific Affairs. Current status of thera-peutic plasmapheresis and related techniques. JAMA 1985;253:819-825.

5. 5. Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, Klein HG, McLeod BC. Clinical appli-cations of therapeutic hemapheresis: an overview of current management. J Clin Apheresis 1993;8:189-194.

6. 6. Smith JW, Weinstein R, Hillyer KL. Therapeutic apheresis: a summary of current indication categories endorsed by the AABB and the American Society for Apheresis: Transfusion 2003;43:820-822.

7. 7. Quillen K, Berkman EM. Introduction to therapeutic apheresis. En: McLeod BC, Price TH, Weinstein R, editors. Apheresis. Principles and practice. Second edition. Bethesda: AABB; 2003. p. 49-69.

8. 8. McCarthy LJ, Danielson C, Fernandez C, Skipworth E, Limiac A, Prahlow T, Goldman J. Intensive plasma exchange for severe autoinmune hemolytic anemia in a four-month-old Infant. J Clin Apheresis 1999;14: 190-192.

9. 9. Verrier J. International Forum. Plasmapheresis en the treatment of systemic lupus erythematosus. Transfus Sci 1996;17(2):283-288.

10. Euler HH, Zeuner RA, Schroeder JO. Plasma ex-change in systemic supus erythematosus. Transfus Sci 1996:17(2):245-265.

11. Kuks JBM, Skallebaek D. Plasmapheresis in myas-thenia gravis. A survey. Transfus Sci 1998;19(2): 129-136.

12. Yeh JH Chiu HC. Optimal volume of processed plasma and total number of selective plasmapheresis sessions in the treatment of patients with severe gene-ralized myasthenia gravis. J Clin Apheresis 1999;14: 177-180.

13. Rund D, Schaap T, Gillis S. Short Communication. Intensive Plasmapheresis for severe trombotic throm-bocytopenic purpura: Long-term clinical outcome. J Clin Apheresis 1997;12:194-195.

14. Rizvi MA, Vesely SK, George JN, Chandler L, Dubai D, Smith JW, Gilcher RO. Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome. Transfusion 2000;40:896-901.

15. Rápale JC, Chevret S, Gajdos P. Plasma exchange in neurological diseases. Transfus Sci 1996;17(2):267-282.

16. Dau PC. The fundamental basis for therapeutic plas-mapheresis in autoimmune diseases. Transfus Sci 1996;17(2):235-244.

17. Sternbach MS, Fawcett S, Wolsley M, Giammarco R. Plasma exchange in chronic inflammatory demy-elinating polyneuropathies. Tranfus Sci 1996;17(3): 415-422.

18. Vamvakas EC, Pineda. Selective extraction of plasma constituents. En McLeod BC, Price TH, Weinstein R, editors. Apheresis: Principles and practice. Second edition Bethesda: AABB; 2003. p. 437-476.

19. Reimann PM, Mason PD. Review articles. Plasma-pheresis: technique and complications. Intensive Care Med 1990;16:3-10.

20. Hester J. Therapeutic Cell Depletion. En: McLeod BC, Price TH, Weinstein R, editors. Apheresis. Prin-ciples and practice. Second edition. Bethesda: AABB; 2003. p. 283 294.

21. McLeod B. Introduction to the third special issue: Clinical applications of therapeutic apheresis. J Clin Apheresis 2000;15:1-5.

22. Everson D, Perry E, Kloster B, Hurley R, Stroncek D. Therapeutic apheresis for babesiosis. J Clin Apheresis 1998;13:32-36.

23. Kim H. Therapeutic pediatric apheresis. J Clin Apheresis 2000;15:129-157.